PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD) heart failure, ischemia, and anemia.
1 - 32 . (canceled)
33 . A method for treating a cancer, comprising administering to a patient having a cancer a compound having a structure:
or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein
R is 3-fluorophenyl;
R 2 is selected from OR 6 and NR 7a R 7b ;
R 6 is selected from hydrogen and methyl; and
R 7a and R 7b are each independently selected from hydrogen, methyl, and ethyl.
34 . The method of claim 3 , wherein the compound is selected from:
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
35 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
36 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
37 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
38 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
39 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
40 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
41 . A method for treating anemia associated with chemotherapy, comprising administering to a patient having a anemia associated with chemotherapy a compound having a structure:
or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein
R is 3-fluorophenyl;
R 2 is selected from OR 6 and NR 7a R 7b ;
R 6 is selected from hydrogen and methyl; and
R 7a and R 7b are each independently selected from hydrogen, methyl, and ethyl.
42 . The method of claim 41 , wherein the compound is selected from:
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
43 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
44 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
45 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
46 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
47 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
48 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.